Red cell exchange transfusion is a well-established and validated treatment often used in adult and pediatric patients with sickle cell disease (SCD). Richard Salisbury, MBChB, MRes, MRCP, MRC Weatherall Institute of Molecular Medicine, Oxford, UK, discusses the findings of a single-center survey aiming to understand how patient care could be improved for individuals receiving transfusion. This led to an investigation into how the prediction of blood needed for transfusion could be optimized. Dr Salisbury highlights that the modeling of hemoglobin S (HbS) dynamics could be a method for achieving this in the future. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.